Ascendis Pharma AS (NAS:ASND)
$ 137.5 -2.81 (-2%) Market Cap: 8.39 Bil Enterprise Value: 8.62 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 71/100

Ascendis Pharma A/S Announces Phase 3 PaTHway Trial Results Conference Call Transcript

Mar 14, 2022 / 12:00PM GMT
Release Date Price: $102.64 (+0.45%)
Operator

Good morning, ladies and gentlemen, and welcome to the Phase III PaTHway Trial Results Conference Call. (Operator Instructions). As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Tim Lee, Senior Director of Investor Relations. Please go ahead.

Timothy Lee;Senior Director of Investor Relations

Yes. Thank you, operator, and thanks, everyone, for joining our Phase III PaTHway Trial Results Conference Call today. I'm Tim Lee, Senior Director, Investor Relations, of Ascendis Pharma.

As part of today's webcast, we have an accompanying slide deck available for download that you can follow on our Investor Relations website. Joining me on today's call is Jan Mikkelsen, President and Chief Executive Officer; Dr. Aimee Shu, Vice President, Clinical Development Endocrine Medical Science; Dr. Dana Pizzuti, Head of Development, Operations and Chief Medical -- Head of Development, Operations and Chief Medical Officer; and Scott Smith, Senior Vice President and Chief Financial Officer.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot